Skip to main content

Advertisement

SpringerLink
Log in

High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population

  • Original Article—Liver, Pancreas, and Biliary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

High-sensitivity C-reactive protein (hs-CRP) has been developed and used as a marker to predict coronary vascular diseases in metabolic syndrome (MS). We investigated whether serum hs-CRP concentration was associated with nonalcoholic fatty liver disease (NAFLD) based on the Akaike Information Criterion (AIC) scoring system, using patients from the human dry dock program.

Methods

From 2004 to 2005, 1254 subjects visited our human dry dock annual checkup program. We excluded from this study individuals with markers of viral hepatitis and those whose alcohol consumption was more than 20 g/week. Finally, 230 subjects (93 men and 137 women) were investigated. Serum hs-CRP concentrations were measured using a highly sensitive latex agglutination assay system. The AIC scoring system with the CATDAP-20 program was introduced to evaluate the parameters that are present frequently in NAFLD.

Results

NAFLD was diagnosed by ultrasound sonography in 35.4% of the men and 18.9% of the women. High serum hs-CRP concentrations were observed in women with NAFLD (normal: NAFLD = 0.45:1.47 mg/l, P < 0.05). Body mass index (BMI), waist circumference, and body weight had the three lowest AIC score (P = 4.5e−19 to 2.6e−16). hs-CRP was the third lowest variable among the serum markers associated with NAFLD (P = 2.3e−6) In addition, the hs-CRP concentration was correlated strongly with triglyceride values in females with NAFLD and with fasting blood glucose, HbA1c, and waist/hip ratio in males with NAFLD (P < 0.05).

Conclusions

The serum hs-CRP concentration was a strong predictor for NAFLD with a low AIC score and correlated with serum markers that indicated lipid and glucose metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Association of Health and Welfare Statistics. Kokumin eiseinodoukou. Tokyo, Japan: Kokumineisei-kyokai, 2003; pp. 87–96.

  2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. Jpn J Gastroenterol. 2003;38:954–61.

    Article  Google Scholar 

  3. The Examination Committee of Criteria for “Obesity Disease” in Japan. Japan Society for Study of Obesity: new criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.

    Google Scholar 

  4. Shimamoto K. Metabolic syndrome: epidemiology. Nippon Naika Gakkai Zasshi. 2004;93:642–7.

    PubMed  Google Scholar 

  5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.

    Article  PubMed  CAS  Google Scholar 

  6. National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III, final report). Circulation 2002;106:3143–421.

    Google Scholar 

  7. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997;349:462–6.

    Article  PubMed  CAS  Google Scholar 

  8. Ridker PM, Hennekens CH, Buring JE, Rify N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.

    Article  PubMed  CAS  Google Scholar 

  9. Block G, Jensen C, Dietrich M, Norkus EP, Hudes M, Packer L. Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J Am Coll Nutr. 2004;23:141–7.

    PubMed  CAS  Google Scholar 

  10. Lowe GD. The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol. 2001;6:1–8.

    Article  PubMed  Google Scholar 

  11. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein concentrations. J Am Coll Cardiol. 2005;46:464–9.

    Article  PubMed  CAS  Google Scholar 

  12. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature (Lond). 2006;444:881–7.

    Article  CAS  Google Scholar 

  13. Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005;69:151–9.

    Article  PubMed  CAS  Google Scholar 

  14. Lim S, Lee HK, Kimm KC, Park C, Shin C, Cho NH. C-reactive protein concentration as an independent risk factor of metabolic syndrome in the Korean population CRP as risk factor of metabolic syndrome. Diabetes Res Clin Pract. 2005;70:126–33.

    Article  PubMed  CAS  Google Scholar 

  15. Santos AC, Lopes C, Guimaraes JT, Barros H. Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes Lond. 2005;29:1452–6.

    Article  PubMed  CAS  Google Scholar 

  16. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. 2005;22:1129–33.

    Article  PubMed  CAS  Google Scholar 

  17. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375–8.

    Article  PubMed  CAS  Google Scholar 

  18. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–21.

    Article  PubMed  Google Scholar 

  19. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52.

    Article  PubMed  Google Scholar 

  20. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–8.

    Article  PubMed  CAS  Google Scholar 

  21. Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004;39:864–9.

    Article  PubMed  CAS  Google Scholar 

  22. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatits, and the metabolic syndrome. Hepatology. 2003;37:917–23.

    Article  PubMed  Google Scholar 

  23. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24:1–6.

    Article  PubMed  CAS  Google Scholar 

  24. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.

    PubMed  CAS  Google Scholar 

  25. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.

    Article  PubMed  Google Scholar 

  26. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154–60.

    Article  PubMed  Google Scholar 

  27. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25:193–7.

    PubMed  CAS  Google Scholar 

  28. Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol. 2004;19:694–8.

    Article  PubMed  CAS  Google Scholar 

  29. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–50.

    Article  PubMed  CAS  Google Scholar 

  30. Lonardo A, Loria P, Leonardi F, POLI.ST.E.N.A. Study Group, et al. Policentrica Steatosi Epatica Non Alcolica. Fasting insulin and uric acid concentrations but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease: a case-control study. Dig Liver Dis. 2002;34:204–11.

    Article  PubMed  CAS  Google Scholar 

  31. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164:2169–75.

    Article  PubMed  Google Scholar 

  32. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020–3.

    Article  PubMed  CAS  Google Scholar 

  33. Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord. 2004;28:167–72.

    Article  PubMed  CAS  Google Scholar 

  34. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. 2nd international symposium on information theory. Budapest: Akademiai Kiado; 1973. pp. 267–81.

    Google Scholar 

  35. Pan W. Akaike’s information criterion in generalized estimating equations. Biometrics. 2001;57:120–5.

    Article  PubMed  CAS  Google Scholar 

  36. Lonardo A, Bellini M, Tartoni P, Tondelli E. The bright liver syndrome: prevalence and determinants of a “bright” liver echopattern. Int J Gastenterol Hepatol. 1997;29:351–6.

    CAS  Google Scholar 

  37. Kogiso T, Moriyoshi Y, Nagahara H. Clinical significance of fatty liver associated with metabolic syndrome. Hepatol Res. 2007;37:711–21.

    Article  PubMed  CAS  Google Scholar 

  38. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54:3140–7.

    Article  PubMed  CAS  Google Scholar 

  39. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72–82.

    Article  PubMed  Google Scholar 

  40. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Mrs. Ohiwa A., Mrs. Moriwaki-Watanabe R., Mrs. Toyota Y., and Ms. Murano K. for their help.

Author information

Authors and Affiliations

  1. Department of General Medicine, International Medical Center of Japan, Tokyo, Japan

    Tomomi Kogiso & Yuriko Moriyoshi

  2. Department of Hygiene and Public Health, Tokyo Women’s Medical University, Tokyo, Japan

    Satoru Shimizu

  3. Aoyama Hospital, Tokyo Women’s Medical University, 2-7-13 Kita-Aoyama, Minato-ku, Tokyo, 107-0061, Japan

    Hikaru Nagahara

  4. Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan

    Tomomi Kogiso & Keiko Shiratori

Authors
  1. Tomomi Kogiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuriko Moriyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoru Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hikaru Nagahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keiko Shiratori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hikaru Nagahara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kogiso, T., Moriyoshi, Y., Shimizu, S. et al. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol 44, 313–321 (2009). https://doi.org/10.1007/s00535-009-0002-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-009-0002-5

Keywords

Search

Navigation